【联邦制药(03933.HK):UBT251注射液完成中国2型糖尿病III期临床研究首例试验参与者给药】智通财经APP讯,联邦制药(03933.HK)发布公告,公司全资附属公司联邦生物科技(珠海横琴)有限公司(“联邦生物科技”)自主研发的 1 类创新药
UBT251 注射液已完成中国 2 型糖尿病 III
期临床研究首例试验参与者给药。本研究将分别进行“UNIGUIDE-1”及“UNIGUIDE-2”两项研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.